Industry Insights

  1. Packed Session Illustrates Reason For Excitement Around Advanced Cancer Therapies

    There are many reasons to be excited by the science being presented at this year’s American Society for Clinical Oncology meeting. The data presented at a special section on Saturday morning opened the door to a future when tumor genetics and biomarkers will change the way we think of about cancer treatment. As a physician working in clinical development, there is also the excitement around intriguing new questions that when answered could lead to life-saving treatments unimaginable just a decade ago. 

    More than 2,000 people packed into a cavernous conference hall at 8 a.m. on Saturday – demonstrating the high level of shared interest in emerging immunotherapies.  

  2. Key Considerations For Companies Outsourcing Their Clinical Packaging Needs

    From virtual biotech companies to large pharmaceutical companies, outsourcing is a key consideration in clinical packaging and distribution. According to Sherpa Clinical Packaging, although outsourcing is a valuable strategy for companies of all sizes and capabilities, it should be entered into for reasons specific to a company’s requirements.

  3. Start Using Your CTMS In A Fraction Of The Time With Significant Cost Savings

    With thousands of people, hundreds of investigative sites, multiple CROs and various eClinical source systems—all generating massive amounts of data—clinical trials are an enormous undertaking. While leading organizations use Clinical Trial Management Systems (CTMS) to centralize operational data and automate processes so they can make better decisions, a CTMS can be out of reach for many small to mid-size companies, leaving them with isolated spreadsheets and/or inefficient, manual practices.

  4. Reducing Study Rescue: The Importance Of Getting Clinical Trials Off To A Good Start

    Clinical trials are not for the faint of heart. Conducting even one clinical trial is a monumental task with complex processes and issues that can surface and derail a study’s timeline. As a result, delays in regulatory filing, market entry, and ultimately, the delivery of new therapies to patients are all too common.

  5. Top 3 Benefits Of Electronic Data Capture Adoption - Infographic

    Electronic Data Capture (EDC), which collects clinical trial data electronically rather than on paper, is becoming an increasingly popular solution for streamlining data processing.

  6. Integrated Workflows: The Unsexy Plumbing Of Clinical Trials

    There is no doubt that clinical research is critical to the advancement of medicine and public health. But conducting such research is a complex, resource intensive endeavor that relies on a multitude of stakeholders, workflows, processes, and information systems.

  7. Does Your Recruitment Strategy Need Re-Routing? 4 Questions to Ask

    In the summer months, we find that a lot of our clients are re-assessing clinical trial recruitment strategies. How is the study tracking to its milestones? What goals have been communicated to senior management?

  8. Adaptive Trials: Is Your Study Equipped To Adapt?

    A traditionally designed clinical trial is, by nature, a roll of the dice. In adaptive trials, however, databases can be unblinded while the study is in progress so that researchers can make changes to certain endpoints as needed. But while more researchers than ever before are investing in electronic data capture (EDC) software to enhance the efficiency of their research, many EDC companies aren’t effective in accommodating adaptive designs.

  9. Silent Partners: How Virtual Clinical Trials Affect the Investigator Site

    Technology and innovation are changing the clinical landscape for both investigators and sites. This is creating both opportunities and challenges for sites regarding their partnering approach with sponsors and CROs. As that landscape continues to change, opportunities to improve the implementation of these technologies will, in turn, help to improve the clinical trial experience for patients.

  10. Fighting The Commoditization Of Sites: It Starts With The Site Initiation Visit (SIV)

    Despite advancements in clinical research technology over the last decade, recent research from the Tufts Center for the Study of Drug Development (CSDD) suggests that we are not conducting site activation any faster today than we did 20 years ago . One of the biggest factors contributing to lengthy cycle times is the inability of sponsors and Contract Research Organizations (CROs) to engage investigative sites in a manner that supports effective patient recruitment and retention in the context of a swift budget and contract process.